

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05372 A2

(51) International Patent Classification⁷: A61K 9/00

(21) International Application Number: PCT/US00/19393

(22) International Filing Date: 14 July 2000 (14.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/144,380 16 July 1999 (16.07.1999) US

(71) Applicant: ALZA CORPORATION [US/US]; 1900
Charleston Road, P.O. Box 7210, Mountain View, California 94039-7210 (US).

(72) Inventors: ABRA, Robert, M.; 143 Judson Avenue, San
Francisco, CA 94112 (US). DIBBLE, Andrew, R.; Apt.
#241, 2951 College Avenue, Livermore, CA 94550 (US).

(74) Agents: SIMBOLI, Paul, B. et al.; ALZA Corporation,
1900 Charleston Road, P.O. Box 7210, Mountain View, CA
94039-7210 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: A LIPOSOME COMPOSITION HAVING RESISTANCE TO FREEZE/THAW DAMAGE

(57) Abstract: A liposome composition having improved protection from freeze/thaw damage is described. The liposome composition contains an osmotic gradient across the liposome lipid bilayer, wherein the osmolarity of the external medium is higher than the osmolarity of the liposome inner medium. Typically, the external medium includes a salt and a cryoprotectant to achieve the increase observed in osmolarity.

**A LIPOSOME COMPOSITION HAVING RESISTANCE
TO FREEZE/THAW DAMAGE**

Field of the Invention

5 The present invention relates to a liposome composition having improved protection against vesicle aggregation, vesicle fusion, and loss of entrapped contents upon freezing and subsequent thawing.

Cross Reference to Related Applications

10 The complete disclosure set forth in the U.S. provisional patent application entitled "Cryoprotection of a Liposome Composition," Serial No.: 60/144,380, filed with the United States Patent and Trademark Office on July 16, 1999, is incorporated herein. The applications are commonly owned.

Background of the Invention

15 Liposomes are closed lipid vesicles used for a variety of purposes. In particular, liposomes may be employed to carry therapeutic agents to a target region or cell by systemic administration of the liposomes. Liposomes have proven particularly valuable to buffer drug toxicity and to alter
20 pharmacokinetic parameters of certain therapeutic compounds, for example, doxorubicin, and amphotericin B. Products that incorporate these compounds are commercially available.

25 The stability and effective storage of pharmaceutical liposome preparations is an important aspect of liposome products. Specifically, it is important that liposome preparations be stored for extended periods of time under appropriate conditions without an undue loss of the encapsulated agent or alteration in size of the liposomes. A concern, however, is that when liposomes are dehydrated or are frozen and subsequently thawed, vesicle fusion and/or leakage of the entrapped contents may occur.

A common method to protect vesicle integrity during dehydration and freezing is to include a cryoprotectant, such as a sugar, in the liposome formulation (Harrigan et al., Chemistry and Physics of Lipids, 52:139-149 (1990)). The cryoprotectant preserves the integrity of the lipids and prevents vesicle fusion and loss of vesicle contents.

U.S. Patent No. 4,927,571, for example, relates to a liposome composition containing doxorubicin which is reconstituted from a lyophilized form that includes between 1 percent (%) and 10% of a cryoprotectant, such as trehalose or lactose.

U.S. Patent No. 4,880,635 relates to a dehydrated liposome composition that is prepared by drying the liposomes in the presence of a sugar, wherein the sugar is present on both the inside and outside surface of the liposome bilayer membrane. Similarly, U.S. Patent No. 5,077,056 relates to a dehydrated liposome composition which includes a protective sugar, preferably on both the internal and external liposome surfaces.

Other liposome formulations, such as DOXIL[®], a liposomal formulation containing doxorubicin, are suspensions wherein the liposomes are not dehydrated for later reconstitution, but remain in a suspension during storage.

The suspension medium, however, typically includes a sugar for protection from freezing damage.

Summary of the Invention

Accordingly, an aspect of the present invention is to provide a liposome composition that is protected from vesicle aggregation and fusion, and protects against a loss of entrapped contents upon freezing and subsequent thawing.

In another aspect, the present invention provides a liposome composition having improved protection from freeze/thaw damage, as evidenced by a reduction in vesicle fusion and a reduction in the loss of

entrapped contents, when compared to the protection provided by the presence of a cryoprotectant alone.

The present invention further provides a liposome composition having an entrapped drug with a high ionic strength that is protected from vesicle
5 fusion and loss of contents upon freezing and subsequent thawing.

In yet another aspect of the invention, a liposome composition is provided having improved protection from freeze/thaw damage. In one embodiment, the composition is composed of a suspension of liposomes, each liposome having an entrapped aqueous medium having an inner
10 osmolarity. The liposomes are suspended in an external medium composed of a water soluble salt and a cryoprotectant, wherein the external medium has an outer osmolarity higher than the inner liposome osmolarity thereby establishing a lower inside/higher outside osmotic gradient across each liposome.

15 In another embodiment, the external medium includes a salt selected from nitrate salts, sodium salts, potassium salts, ammonium salts, and sulfate salts. In a preferred embodiment, the salt is sodium chloride (NaCl) or potassium chloride (KCl).

The cryoprotectant is typically a sugar, either a monosaccharide or a
20 disaccharide, glycerol, or polyethyleneglycol. In a preferred embodiment, the cryoprotectant is selected from trehalose, maltose, sucrose, glucose, lactose, dextran, glycerol, polyethyleneglycol, and aminoglycosides.

In another embodiment, the composition further includes a therapeutic agent entrapped in the liposomes. In a preferred embodiment, the
25 therapeutic agent is cisplatin, or a cisplatin analogue, or derivative thereof.

In still another embodiment, the liposome composition includes a vesicle-forming lipid derivatized with a hydrophilic polymer chain.

In another aspect, the invention provides a method for protecting a liposome composition from freeze/thaw damage. The method includes

preparing a suspension of liposomes, each liposome in the suspension having an entrapped aqueous medium having an inner osmolarity. The liposomes are suspended in an external medium composed of a water soluble salt and a cryoprotectant, wherein the external medium has an outer osmolarity higher than the inner liposome osmolarity thereby establishing a lower inside/higher outside osmotic gradient across each liposome.

In still another aspect, the invention provides a method for protecting a liposome composition containing a metal coordination compound against freeze/thaw damage. The method includes preparing a suspension of liposomes, each liposome in the suspension having an entrapped aqueous medium having an inner osmolarity and an entrapped compound. The liposomes are suspended in an external medium composed of a water soluble salt and a cryoprotectant, wherein the external medium has an outer osmolarity higher than the inner liposome osmolarity thereby establishing a lower inside/higher outside osmotic gradient across each liposome. In one embodiment, the therapeutic agent is cisplatin, or a cisplatin analogue or derivative thereof. In another embodiment, the salt in the external medium is sodium chloride (NaCl) and the cryoprotectant is sucrose.

In yet another aspect, the invention provides a method for improving cryoprotection of a suspension of liposomes that includes a cryoprotectant in the suspension medium. The improvement includes a water soluble salt in the suspension medium effective to establish an osmotic gradient across each liposome, wherein the suspension medium has a higher osmolarity than the liposome interior. In one embodiment, the osmotic gradient is at least about 100 mOsm, preferably greater than about 200 mOsm, more preferably greater than about 400 mOsm, and most preferably greater than about 500 mOsm.

Detailed Description of the Invention

I. Definitions

As used herein, the following terms have the following meanings:

"Freezing damage" or "freeze damage" refers to any one of several
5 undesirable effects that occur upon the exposure of a liposome composition to
a temperature sufficient to cause one of the undesirable effects. A sufficient
temperature that results in freezing damage is typically a temperature lower
than about 0°C, more typically a temperature lower than about -5°C, and even
more typically a temperature lower than about -10°C. Undesirable effects
10 include, but are not limited to, an increase in particle size growth due to
aggregation and/or fusion of vesicles, and loss of an encapsulated therapeutic
agent. The actual temperature which can cause onset of such an effect will
vary according to the liposome formulation, e.g., the type of lipids and other
bilayer components, as well as the entrapped medium and therapeutic agent.
15 Sometimes freezing damage is less at very cold temperatures, particularly if the
rate of freezing and subsequent thawing is rapid.

"Freeze/thaw damage," as used herein, includes the undesirable side
effects that are associated with freezing damage (described above), and
additional effects observed as a result of at least one freezing and thawing
20 cycle, e.g., a non-homogeneous particle size distribution. Described effects
may be more pronounced during a slow thawing process, i.e., at about 2-8°C,
versus a more rapid thawing process, i.e., at room temperature, or exposure to
a water bath. (See, for example, Table 8).

"Cryoprotectant" refers to an agent or compound suitable to protect a
25 liposome composition from freezing damage and/or freeze/thaw damage.
Preferred cryoprotectants include, for example, sugars (disaccharides and
monosaccharides), glycerol, and polyethylene glycol.

"Osmotic gradient" values, as reported herein, were determined by

calculating inner and outer osmolarity of the liposome composition, taken as the molarity times one ($M \times 1$) for a nonelectrolyte or the number of ions per molecule for an electrolyte, in both the inner and outer liposome media and subtracting the inner osmolarity from the outer osmolarity.

5

II. Exemplary Liposome Compositions

As described above, the present invention relates to liposome compositions exhibiting resistance to freezing damage and/or freeze/thaw damage. The liposome compositions have an osmotic gradient across the liposome lipid bilayer, wherein the suspension medium external to the liposome has a higher osmolarity than the osmolarity of the medium entrapped within the liposome.

For example, Example 1 (below) describes the preparation of two placebo liposome formulations, i.e., one liposome formulation having the cryoprotectant sucrose in both the internal and external liposome media, and the other liposome formulation having sucrose present in the external medium only. Both liposome formulations had 0.9% weight/volume (w/v) NaCl present in the liposome interior and exterior media, and the liposomes were composed of the lipids HSPC, cholesterol, and mPEG-DSPE in a molar ratio of 51/44/5, respectively.

The two liposome formulations were frozen at -20°C for 2.7 days (approximately 65 hours) and subsequently thawed by resting at room temperature. Dynamic light scattering was performed on the two placebo liposome formulations to determine particle size before and after freezing. The results are shown in Table 1.

Table 1

Formulation #	Internal [sucrose] (%; w/v)	External [sucrose] (%; w/v)	Osmotic Gradient (mOsm)	Sample History	Mean Particle* Size (nm)
1 (control)	0	5	146	never frozen	116.7 ± 0.6
1	0	5	146	frozen	166.3 ± 3.6
2 (control)	5	5	0	never frozen	116.3 ± 3.1
2	5	5	0	frozen	203.8 ± 4.5

*Mean particle size is the standard deviation of three measurements on a single sample.

5 The liposome formulation that had sucrose present in the internal and external media (formulation #2), was more susceptible to freezing damage as evidenced by the increase in particle size, i.e., from approximately 116 nm (the never frozen control) to 204 nm for the freeze/thaw sample. The liposome formulation containing sucrose in the external medium alone
10 (formulation #1), yielded a smaller particle size increase after freezing to approximately 166 nm. As will be more fully demonstrated in the Examples below, these results suggest that a liposome formulation having a hyperosmotic gradient, i.e., an external osmolarity greater than internal osmolarity, (e.g., formulation #1 which has an osmotic gradient of 146
15 mOsm), was less susceptible to freeze/thaw damage.

Example 2 describes the preparation of a placebo liposome formulation with the above-described lipid composition containing 5% (w/v) sucrose externally and containing no sucrose internally. The liposome formulation was subsequently diluted with 5% (w/v) sucrose and varying amounts of NaCl
20 to yield liposome formulations having 0.9%, 0.6%, and 0.3% (w/v) NaCl in the external aqueous medium. The NaCl concentration in the internal aqueous medium was 0.9% (w/v). Samples of each liposome formulation were frozen at -20°C for approximately 5 days (approximately 118 hours), and subsequently thawed. Particle size was determined, and the results are

shown below in Table 2.

Table 2

External [NaCl] (%; w/v)	External [sucrose] (%; w/v)	Osmotic Gradient (mOsm)	Sample History	Mean Particle Size* (nm)
0.9	5	146	never frozen control	114.3 \pm 1.5
0.9	5	146	frozen	134.3 \pm 2.1
0.6	5	43	frozen	138.3 \pm 1.5
0.3	5	-59	frozen	143.7 \pm 1.2

*Mean particle size is the standard deviation of three measurements on a single sample.

The data shown in Table 2 reveal that the extent of freeze/thaw damage, as determined by the increase in particle size after freezing, is influenced by the osmotic gradient across the liposome lipid bilayer. The liposome formulation having an external medium of 5% sucrose and 0.9% NaCl (osmotic gradient = 146 mOsm), was the least susceptible to freeze/thaw damage, as evidenced by the smallest increase in particle size of the three liposome formulations. The liposome formulation with a reversed osmotic gradient, that is the formulation with 5% sucrose and 0.3% NaCl in the external medium (osmotic gradient = -59 mOsm), had the largest increase in particle size upon freezing and thawing.

Example 3 describes a qualitative test on 24 liposome formulations to further assess the importance of an osmotic gradient on the susceptibility of a liposome formulation to freeze/thaw damage. In this example, placebo liposome formulations having the above lipid composition (HSPC, cholesterol and mPEG-DSPE) were prepared. The internal liposome medium was either 0.9% or 1.8% (w/v) NaCl. The external aqueous medium contained: (i) 10 millimolar (mM) histidine, (ii) 0%, 5% or 10% (w/v) sucrose, and (iii) a NaCl concentration equal to the internal NaCl concentration multiplied by 0.5, 1, 1.5 or 2.0. The internal and external media of each formulation are set forth in

Table 3.

Table 3

Sample #	Internal [NaCl] (%; w/v)	External [NaCl] (%; w/v)	External [sucrose] (%; w/v)	External Osmolarity (mOsm)	Osmotic Gradient (mOsm)	Visual Appearance after Freezing ¹
1	0.9	0.45	0	164	-144	particles
2	0.9	0.45	5	310	2	turbid
3	0.9	0.45	10	456	148	turbid
4	0.9	0.9	0	318	10	turbid
5	0.9	0.9	5	464	156	turbid
6	0.9	0.9	10	610	302	nc
7	0.9	1.35	0	472	164	nc
8	0.9	1.35	5	618	310	nc
9	0.9	1.35	10	764	456	nc
10	0.9	1.8	0	626	318	nc
11	0.9	1.8	5	772	464	nc
12	0.9	1.8	10	918	610	nc
13	1.8	0.9	0	318	-298	particles
14	1.8	0.9	5	464	-152	particles
15	1.8	0.9	10	610	-6	turbid
16	1.8	1.8	0	626	10	turbid
17	1.8	1.8	5	772	156	turbid
18	1.8	1.8	10	918	302	nc
19	1.8	2.7	0	934	318	nc
20	1.8	2.7	5	1080	464	nc
21	1.8	2.7	10	1226	610	nc
22	1.8	3.6	0	1242	626	nc
23	1.8	3.6	5	1388	772	nc
24	1.8	3.6	10	1534	918	nc

¹nc = no significant change in visual appearance compared to unfrozen control; *particles* = visual presence of macroscopic particles; *turbid* = sample was less translucent than unfrozen control.

The samples shown in Table 3 were frozen at -20°C for 3 hours and subsequently thawed to room temperature. Each sample was visually inspected for macroscopic evidence of freezing damage, such as the presence of macroscopic particles, and for clarity of the suspension. The samples having a hypo-osmotic gradient (sample numbers 1, and 13-14 in Table 3, where the external osmolarity is less than the internal osmolarity), were visually heterogeneous with macroscopic particles visible after freezing and thawing. In contrast, liposome formulations having a hyper-osmotic gradient (sample numbers 3, 5-12, and 17-24 in Table 3), were visually similar to the unfrozen control samples. Nearly iso-osmotic samples (sample numbers 2, 4, and 15-16 in Table 3), had an intermediate appearance with not as many particles present as compared with the hypo-osmotic samples, but not as visually clear as the control. It is worth noting that the nearly iso-osmotic sample (sample #16) having 1.8% internal and external NaCl, was intermediate in appearance, indicating that protection from freezing damage is not simply a result of an increase in the external NaCl concentration, but is also the result of a hyper-osmotic gradient across the liposome lipid bilayer.

In another experiment performed in support of the invention, and described in Example 4, liposome formulations containing cisplatin were prepared. The liposomes were composed of HSPC, cholesterol, and mPEG-DSPE in a 51/44/5 molar ratio, respectively. Entrapped in the liposomes was cisplatin in a 0.9% (w/v) NaCl solution. The external bulk suspension medium was composed of 10 mM histidine, NaCl at a concentration of 0.9%, 1.8%, 2.7%, or 3.6% (w/v), and sucrose at a concentration of 5%, 10%, 15%, or 20% (w/v). The exemplary formulations are set forth in Table 4. The liposome samples were frozen at -20°C for 6.8 days (approximately 118 hours), and then thawed by resting at room temperature. The mean particle size of the liposomes in each sample was determined as a measurement of the extent of freeze damage. The results are shown in Table 4.

Table 4

External [sucrose] (% w/v)	External [NaCl] (%; w/v)	Osmotic Gradient (mOsm)	Mean Particle Size (nm); never frozen	Mean Particle Size (nm); frozen at -20 °C 6.8 days	Increase in Mean Particle Size due to freezing* (nm)
5	0.9	156	112.3 ± 2.5	1450 ± 870	1340 ± 870
5	1.8	464	106.3 ± 0.6	133.7 ± 0.6	27.4 ± 1.2
5	2.7	772	104.3 ± 1.5	109.7 ± 1.5	5.4 ± 3.0
5	3.6	1080	103.3 ± 2.1	104.7 ± 2.3	1.4 ± 4.4
10	0.9	302	110.7 ± 0.6	169.3 ± 1.5	58.6 ± 2.1
10	1.8	610	104.7 ± 1.2	138.3 ± 1.5	33.6 ± 2.7
10	2.7	918	102.7 ± 1.5	115.7 ± 2.3	13.0 ± 3.8
10	3.6	1226	104.3 ± 1.2	110.7 ± 0.6	6.4 ± 1.8
15	0.9	448	108.3 ± 1.2	169.7 ± 0.6	61.4 ± 1.8
15	1.8	756	104.0 ± 1.0	132.0 ± 2.0	28.0 ± 3.0
15	2.7	1064	105.0 ± 1.0	120.7 ± 1.2	15.7 ± 2.2
15	3.6	1372	103.3 ± 2.1	111.0 ± 1.0	7.7 ± 3.1
20	0.9	594	104.3 ± 0.6	139.3 ± 1.5	35.0 ± 2.1
20	1.8	902	105.3 ± 1.2	123.7 ± 2.5	18.4 ± 3.7
20	2.7	1210	104.0 ± 1.0	123.3 ± 1.5	19.3 ± 2.5
20	3.6	1518	103.7 ± 1.5	113.3 ± 1.5	9.6 ± 3.0

*Mean particle size is the standard deviation of three measurements on a single sample.

5 As shown in Table 4, the increase in mean particle size upon a single freeze/thaw cycle is less when the external NaCl concentration is increased above that of isotonic, i.e., 0.9% (w/v), NaCl. At each concentration of sucrose, e.g. 5%, 10%, 15% and 20% (w/v), the higher the NaCl concentration, the better the liposome vesicles were protected from freeze/thaw damage. The
10 external composition which provided the best protection from freezing damage

was at 5% (w/v) sucrose, and 3.6% (w/v) NaCl, wherein the particle had no statistical increase in particle size.

As evidenced by the data shown in the fourth column of Table 4, even in the absence of freezing, the mean particle size decreased measurably with increasing external osmolarity. Experiments herein indicate that the decrease in size is not the result of a change in liposome shape. While liposome shrinkage is expected in the presence of a hyperosmotic gradient, due to the expulsion of water, a change in liposome shape should not persist after the 300-fold dilution with 0.9% (w/v) NaCl which occurs prior to the particle size measurement by dynamic light scattering. Experiments showed that diluting hypertonic formulations with 3.6% (w/v) NaCl or with distilled water, resulted in the same measured mean particle size as samples diluted with 0.9% (w/v) NaCl. This suggests that the decrease in measured particle size with increasing osmolarity is primarily due to a change in the aggregation state of the vesicles.

A surprising result shown in Table 4, is that increasing the external sucrose concentration did not significantly decrease the extent of particle size growth upon freezing and thawing, particularly when the external NaCl concentration was greater than or equal to 1.8% (w/v). When the external NaCl concentration was 2.7% or 3.6%, the data suggest that a lower external sucrose concentration may offer the best protection from freezing damage for this particular liposome composition. This point was further investigated by preparing liposome formulations having the same composition as set forth in Example 4, except that the external sucrose concentration was either 1%, 2%, 3%, 4%, or 5% (w/v). The samples were frozen at -20°C for 3.9 days (approximately 94 hours), and thawed to room temperature, and the extent of freezing damage was determined by measuring mean particle size before and after freezing. Results are shown in Table 5.

Table 5

External [sucrose] (% w/v)	External [NaCl] (%; w/v)	Osmotic Gradient (mOsm)	Mean Particle Size (nm); never frozen	Mean Particle Size (nm); frozen at -20 °C 3.9 days	Increase in Mean Particle Size due to freezing* (nm)
1	1.8	347	109.7 ± 0.6	225.0 ± 2.6	115.3 ± 3.2
1	2.7	655	106.7 ± 1.2	114.7 ± 0.6	8.0 ± 1.8
1	3.6	963	103.7 ± 1.2	106.0 ± 0.0	2.3 ± 1.2
2	1.8	376	108.7 ± 2.3	199.0 ± 2.6	90.3 ± 4.9
2	2.7	684	107.0 ± 1.0	112.7 ± 1.2	5.7 ± 2.2
2	3.6	992	104.3 ± 0.6	104.7 ± 0.6	0.4 ± 1.2
3	1.8	406	109.0 ± 0.0	174.3 ± 1.2	65.3 ± 1.2
3	2.7	714	107.0 ± 0.0	108.0 ± 1.0	1.0 ± 1.0
3	3.6	1022	105.0 ± 0.0	104.0 ± 1.0	-1.0 ± 1.0
4	1.8	435	111.0 ± 1.0	160.3 ± 0.6	49.3 ± 1.6
4	2.7	743	104.7 ± 1.5	108.3 ± 0.6	3.6 ± 2.1
4	3.6	1051	105.3 ± 0.6	105.7 ± 0.6	0.4 ± 1.2
5	1.8	464	110.7 ± 1.2	142.7 ± 1.5	32.0 ± 2.7
5	2.7	772	106.0 ± 1.7	106.7 ± 1.2	0.7 ± 2.9
5	3.6	1080	104.0 ± 1.0	105.0 ± 1.0	1.0 ± 2.0

*Mean particle size is the standard deviation of three measurements on a single sample.

The results shown in Table 5 are consistent with the results shown in Table 4, showing that at high external NaCl concentrations, the optimum

external sucrose concentration for cryoprotection is relatively low for this particular liposome formulation.

The experiments described above focus primarily on particle size growth upon freezing and subsequent thawing, as evidenced by the extent of freeze/thaw damage. Additional experiments, described herein, relate to the loss of an entrapped therapeutic agent to assess the extent of freeze/thaw damage. In this experiment, some of the samples tested for the data of Table 5 were further analyzed for percent of drug encapsulation before and after freezing. The percent of entrapped cisplatin was measured by flame atomic absorption spectroscopy as described in the methods section below. The results are set forth in Table 6.

Table 6

External [sucrose] (%; w/v)	External [NaCl] (%; w/v)	Sample History (frozen or never frozen)	Increase in Mean Particle Size Due to Freezing (nm); from Table 5*	% Encapsulation
1	1.8	never frozen control	not applicable	100
1	1.8	frozen	115.3 \pm 3.2	91
-----	-----	-----	-----	-----
3	1.8	frozen	65.3 \pm 1.2	91
3	2.7	frozen	1.0 \pm 1.0	98
3	3.6	frozen	-1.0 \pm 1.0	98

*Mean particle size is the standard deviation of three measurements on a single sample.

The correlation between percent encapsulation of cisplatin and mean particle size growth is evident. For example, release of cisplatin upon freezing and subsequent thawing was found to occur when there was particle size growth, i.e., increase as measured by dynamic light scattering (DLS).

To ensure that a small number of relatively large particles were not formed

during freezing, turbidity measurements at 650 nm were performed (as detailed in the methods section below). Turbidity measurements are generally more sensitive than dynamic light scattering to small portions of large particles in a sample. Liposomes were prepared as described in Example 4, but with the external sucrose concentration held constant at 3% (w/v). The range of external NaCl concentrations is set forth in Table 7. The samples were frozen at -20°C for 3.9 days (approximately 93 hours), and thawed by resting at room temperature. The samples were then analyzed by DLS and turbidity determination, and compared to a control, i.e., a sample that was never frozen. The results are shown in Table 7 below.

Table 7

External [NaCl] (% w/v)	OD _{650 nm} (never frozen)	OD _{650 nm} (previously frozen)	Relative Change in Turbidity Due to Freezing and Thawing	Increase in Mean Particle Size Due to Freezing and Thawing (nm)*
1.8	0.603	2.200	3.65	58.7 ± 7.4
2.1	0.621	1.174	1.89	29.0 ± 3.0
2.4	0.647	0.738	1.14	6.4 ± 1.2
2.7	0.667	0.711	1.07	5.3 ± 2.5
3.0	0.667	0.676	1.01	2.0 ± 1.2
3.3	0.675	0.674	1.00	1.3 ± 2.6
3.6	0.675	0.687	1.02	3.0 ± 1.2

*Mean particle size is the standard deviation of three measurements on a single sample.

15

The relative change in turbidity caused by one freeze/thaw cycle is determined by the ratio of turbidity_(frozen and thawed) to turbidity_(never frozen). Comparing the last two columns of Table 7, the correlation between mean particle size growth and relative change in turbidity due to protection from freezing and thawing is evident. The data suggest the resistance to freeze/thaw damage

20

provided by the presence of an osmotic gradient across the liposome bilayer is good, particularly when the external sucrose concentration is between about 1% to about 10%, more preferably between about 1% and about 5%, and most preferably between about 2% to about 4%, in the presence of greater than
5 about 3% (w/v) NaCl.

In particular, the liposomal composition containing cisplatin used in the experiments described above, is protected from freeze/thaw damage in the presence of an external medium having between about 2.7% to about 3.6% (w/v) NaCl, and between about 2% to about 5% sucrose.

10 In an additional experiment, liposome formulations containing various amounts of a cryoprotectant and salt, were exposed to different freeze/thaw conditions. Liposomes were prepared from HPSC, mPEG-DSPE, and cholesterol as previously described. Cisplatin in a 0.9% (w/v) NaCl solution was entrapped in the liposomes and the external medium was adjusted to
15 contain 3.3% (w/v) NaCl and 3% (w/v) sucrose. Samples were prepared in triplicate and were frozen by several methods, including: (i) dry ice/isopropanol bath for about 10 minutes, followed by incubation in a -70°C freezer; (ii) dry ice/isopropanol followed by incubation in a -20°C freezer; (iii) stored directly in a -70°C freezer; (iv) stored directly in a -35°C freezer; and (v) stored directly in a -
20 20°C freezer. After 3.9 days, (approximately 94 hours), all of the samples were subsequently thawed. From each set of triplicates, one sample was thawed in room temperature water, one sample was thawed in room temperature air, and one sample was thawed in a 2-8°C refrigerator. All samples were assessed for freeze/thaw damage by measuring particle size by DLS. The only samples
25 which exhibited measurable size growth were those samples frozen at -70°C, either directly, or after introducing to a dry ice/isopropanol bath followed by incubation in a -70°C freezer. The size growth was dependent on both the freezing and the thawing conditions, with the slower rates of freezing and thawing causing the most freeze/thaw damage, as shown below in Table 8.

Table 8

Freezing Conditions	Thawing Conditions	Sample ¹ History (Frozen or Never Frozen)	Mean Particle Size (nm)*	Size Growth (nm) after Freezing and Thawing
N.A. ²	N.A.	never frozen control	89.5 ± 0.7	N.A.
DI/IPA, -70	RT water	frozen	90.3 ± 1.4	0.8 ± 2.1
DI/IPA, -70	RT air	frozen	92.4 ± 1.9	2.9 ± 2.6
DI/IPA, -70	2-8 °C air	frozen	97.0 ± 1.8	7.5 ± 2.5
-70 °C directly	RT water	frozen	91.1 ± 1.8	1.6 ± 2.5
-70 °C directly	RT air	frozen	97.3 ± 1.3	7.8 ± 2.0
-70 °C directly	2-8 °C air	frozen	100.3 ± 0.6	10.8 ± 1.3

¹All liposomes have osmotic gradient of 919 mOsm (0.9% internal NaCl; 3.3% external NaCl + 3% external sucrose + 10 mM external histidine; cisplatin is assumed to be predominantly precipitated.)

²Abbreviations: N.A. = not applicable; DI/IPA, -70 = dry ice/isopropanol then placed in -70°C freezer; RT = room temperature.

*Mean particle size is the standard deviation of three measurements on a single sample.

This experiment suggests that liposome compositions having an osmotic gradient are protected against freeze/thaw damage to temperatures of at least -35°C.

The above experiments have demonstrated that an osmotic gradient across the liposome bilayer provides protection against freeze/thaw damage to the liposome compositions. However, it is also necessary that the osmotic gradient does not affect the stability of the liposome composition under non-freezing conditions. To assess the stability of the liposome compositions having an osmotic gradient, samples were placed in an accelerated stability test. Specifically, two lots of liposome compositions were prepared as

described in Example 4. The liposome compositions contained HSPE, mPEG-DSPE, and cholesterol with entrapped cisplatin. The external aqueous suspension medium was composed of 3.3% (w/v) NaCl, and 3% (w/v) sucrose.

Table 9 shows the components and concentrations for test Batches 1 and 2,
5 and for the control formulation.

Table 9

Component	Concentration in mg/ml for Test Batch 1 and 2	Concentration in mg/ml for Control
cisplatin	1.0	1.0
HSPC	40.0	40.0
cholesterol	17.1	17.1
mPEG-DSPE	14.3	14.3
sucrose	25.5	0
NaCl	29.4	9
histidine	1.55	1.55

10 The two test batches and the control formulation were stored at various temperatures (as shown in Table 10) for up to 3.5 months. At intervals during this 3.5 month period, samples were removed for analysis by DLS to determine the percent of encapsulated cisplatin and mean particle size. The results are summarized in Table 10.

15

Table 10

batch #	Storage Temperature	Incubation Time	[Cisplatin] (mg/ml)	Percent Encapsulation	Mean Particle Size* (nm)
1	N.A.	time zero	0.897 ± 0.006	100.0 ± 0.0	N.D.
1	+20 °C	1 month	0.900 ± 0.000	99.7 ± 0.6	98.5 ± 1.6
1	+20 °C	2 months	0.877 ± 0.006	99.3 ± 0.6	98.4 ± 1.2
1	+20 °C	3 months	0.877 ± 0.006	98.7 ± 0.6	97.7 ± 1.1
1	+20 °C	3.5 months	0.907 ± 0.006	N.D.	N.D.
1	2-8 °C	1 month	0.91	100	104.0 ± 1.7
1	2-8 °C	2 months	0.89	100	100.0 ± 0.9
1	2-8 °C	3 months	0.93	100	100.2 ± 0.8
1	-20 °C	1 week	0.89	94	102.3 ± 2.1
1	-20 °C	2 weeks	0.89	91	110.3 ± 1.2
1	-20 °C	1 months	0.90	88	108.3 ± 1.5
1	-20 °C	2 months	0.87	87	110.7 ± 2.3
1	-20 °C	3 months	0.89	84	111.7 ± 0.6
2	N.A.	time zero	0.930 ± 0.000	99	N.D.
2	+20 °C	1.3 months	0.950 ± 0.000	99.0 ± 0.0	100.8 ± 2.1
2	+20 °C	2.3 months	0.895 ± 0.005	97.0 ± 0.0	100.8 ± 0.8
2	+20 °C	3.3 months	0.930 ± 0.010	96.3 ± 0.6	101.1 ± 0.8
2	2-8 °	1.3 months	0.99	99	103.7 ± 1.2
2	2-8 °	2.3 months	0.94	99	99.9 ± 1.2
2	2-8 °	3.3 months	1.00	99	100.6 ± 1.6
2	-20 °C	2 weeks	0.935 ± 0.005	95.5 ± 0.5	102.7 ± 1.2
2	-20 °C	1.3 months	0.93	94	104.7 ± 0.6
2	-20 °C	2.3 months	0.88	93	102.0 ± 1.0
2	-20 °C	3.3 months	0.93	93	101.0 ± 1.0

5 *Mean particle size is the standard deviation of three measurements on a single sample.

Table 10 illustrates, inter alia, that freezing batch #1 at -20°C for one week resulted in a 6% drop in the amount of encapsulated drug. In this sample, after

2 weeks of freezing, the percent of encapsulated drug lost was 9%. As shown, the mean particle size at these time points had only a slight increase. Infusion of a product exhibiting a 9% loss of the selected entrapped drug demonstrating little change in the particle size should not compromise efficacy, or patient
5 safety, as a majority of the drug is entrapped in the liposomes. As shown, batch #2 exhibited even less leakage than bath #1.

The stability tests indicate that a liposome composition having an osmotic gradient across the lipid bilayer, wherein the outer liposome osmolarity is higher than the inner osmolarity, provides additional protection from accidental
10 freezing damage during product shipment, with negligible effect on product stability.

III. Liposome Components

A. Lipids

15 In the studies discussed above employing an osmotic gradient, i.e., wherein the outer liposome osmolarity is higher than the inner osmolarity, to decrease liposome susceptibility to freezing damage, was demonstrated using liposomes composed of hydrogenated soy phosphatidylcholine (HSPC), cholesterol and mPEG-DSPE. It will be appreciated by one of skill in the art,
20 however, that liposome compositions, composed of a variety of lipid compositions are contemplated. Liposomes are composed primarily of vesicle-forming lipids, i.e., lipids that can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids. The vesicle-forming lipids of this type preferably have two hydrocarbon chains, typically acyl chains, and a head
25 group, either polar or nonpolar. There are a variety of synthetic vesicle-forming lipids and naturally-occurring vesicle-forming lipids, including the phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, phosphatidylinositol, and sphingomyelin, wherein the two hydrocarbon chains are typically between about 12-22 carbon

atoms in length, and have varying degrees of unsaturation. The above-described lipids and phospholipids whose acyl chains have varying degrees of unsaturation can be obtained commercially or prepared according to published methods. References for lipid synthesis include: (i) Mason et al., "A method for
5 the synthesis of isomerically pure saturated mixed-chain phosphatidylcholines," Anal. Biochem., 113(1):96-101 (1981); (ii) Zalipsky, S. "Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafter liposomes," Bioconjug. Chem., 4(4): 296-299 (1993).

The liposomes can also include a lipid that is stably incorporated into the
10 liposome lipid bilayer, such as diacylglycerols, lyso-phospholipids, fatty acids, glycolipids, cerebroside and sterols, such as cholesterol.

If desired, the liposome can also include a vesicle-forming lipid derivatized with a hydrophilic polymer, as described, for example, in U.S. Patent No. 5,013,556. Including a derivatized lipid in the liposome
15 composition forms a surface coating of hydrophilic polymer chains around the liposome. The surface coating of hydrophilic polymer chains is effective to increase the *in vivo* blood circulation lifetime of the liposomes when compared to liposomes lacking such a coating.

Vesicle-forming lipids suitable for derivatization with a hydrophilic
20 polymer include any of those lipids listed above, and, in particular phospholipids, such as distearoyl phosphatidylethanolamine (DSPE).

Hydrophilic polymers suitable for derivatization with a vesicle-forming lipid include polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, poly-
25 hydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxypropylmethacrylate, polyhydroxyethylacrylate, hydroxymethylcellulose, hydroxyethylcellulose, polyethyleneglycol, polyaspartamide and hydrophilic peptide sequences. The polymers may be employed as homopolymers, copolymers, and block or random copolymers.

A preferred hydrophilic polymer chain is polyethyleneglycol (PEG), preferably as a PEG chain having a molecular weight between about 500 daltons to about 10,000 daltons, more preferably between about 1,000 daltons to about 5,000 daltons. Methoxy or ethoxy-capped analogues of PEG
5 are also preferred hydrophilic polymers, commercially available in a variety of polymer sizes, e.g., about 120 daltons to about 20,000 daltons.

Preparation of vesicle-forming lipids derivatized with hydrophilic polymers has been described, for example, in U.S. Patent No. 5,395,619. Preparation of liposomes including such derivatized lipids has also been
10 described, which typically contain between about 1-20 mole percent of such a derivatized lipid included in the liposome composition.

B. Entrapped Agent

The liposomes also typically include an entrapped agent, and/or drug,
15 wherein "entrapped" is intended to include encapsulation of the agent and/or drug in the aqueous core and aqueous spaces of liposomes, in addition to entrapment of the agent and/or drug in the lipid bilayer(s) of the liposomes.

Agents and/or drugs contemplated for use in the liposome composition of the invention are widely varied, and include, for example, both therapeutic
20 and diagnostic applications.

Therapeutic agents and/or drugs include natural and synthetic compounds having the following therapeutic activities: anti-arthritis, anti-arrhythmic, anti-bacterial, anticholinergic, anticoagulant, antidiuretic, antidote, antiepileptic, antifungal, anti-inflammatory, antimetabolic, antimigraine,
25 antineoplastic, antiparasitic, antipyretic, antiseizure, antisera, antispasmodic, analgesic, anesthetic, beta-blocking, biological response modifying, bone metabolism regulating, cardiovascular, diuretic, enzymatic, fertility enhancing, growth-promoting, hemostatic, hormonal, hormonal suppressing, hypercalcemic alleviating, hypocalcemic alleviating, hypoglycemic alleviating,

hyperglycemic alleviating, immunosuppressive, immunoenhancing, muscle relaxing, neurotransmitting, parasympathomimetic, sympathomimetic plasma extending, plasma expanding, psychotropic, thrombolytic and vasodilating.

In a preferred embodiment, the entrapped agent is a "cytotoxic drug",
5 that is, a drug having a deleterious or toxic effect on targeted cells.

Exemplary cytotoxic agents include the anthracycline antibiotics such as doxorubicin, daunorubicin, epirubicin and idarubicin, and analogs of these, such as epirubidin and mitoxantrone; platinum compounds, such as cisplatin, carboplatin, ormaplatin, oxaliplatin, zeniplatin, enloplatin, lobaplatin,
10 spiroplatin, ((-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutane dicarboxylato)platinum)(DWA2114R), (SP-4-3(R)-1,1-cyclobutane-dicarboxylato(2-)-(2-methyl-1,4-butanediamine-N,N'))platinum) (CI-973), nedaplatin (254-S) and (bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV)) (JM-216) (Weiss et al., Drugs, 46(3):360-377 (1993)); and vinca
15 alkaloids, such as vincristine, vinblastine, vinleurosine, vinrodisine, vinorelbine (navelbine) and vindesine.

Another group of cytotoxic agents are the topoisomerase I inhibitors, such as camptothecin and its analogues, including SN-38 ((+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-
20 3,14(4H,12H)-dione); 9-aminocamptothecin; 9-nitrocamptothecin, topotecan (hycamtin; 9-dimethyl-aminomethyl-10-hydroxycamptothecin); irinotecan (CPT-11; 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin), which is hydrolyzed *in vivo* to SN-38); 7-ethylcamptothecin and its derivatives (Sawada et al., Chem. Pharm. Bull., 41(2):310-313 (1993)); 7-chloromethyl-
25 10,11-methylene-dioxy-camptothecin; and others (SN-22, Kunimoto et al., J. Pharmacobiodyn., 10(3):148-151 (1987); DX-8951f and GG-211 ((7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(S)-camptothecin)) (Rothenberg, Ann. Oncol., 8(9):837-855 (1997)), and 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin (Chong Kun Dang Corp., Seoul

Korea, CKD602).

In a preferred embodiment of the invention, the composition is used for protection of liposomes entrapping a therapeutic agent and/or drug, having a high ionic strength, such as cisplatin and its related analogues, recited above.

5

C. Salt and Cryoprotectant

The external suspension medium of the liposome composition typically has a higher osmolarity than the osmolarity of the internal liposome medium. The increased osmolarity is provided primarily by the addition of a salt to the
10 external medium. Any water soluble salt is suitable for this purpose. For example, salts selected from nitrate salts, sodium salts, potassium salts, ammonium salts, and sulfate salts are contemplated. In a preferred embodiment, the salt is NaCl or KCl.

The external medium also includes a cryoprotectant, generally defined
15 above to include sugars, glycerol, and polyethyleneglycol. The sugar can be a disaccharide or a monosaccharide, and exemplar sugars include trehalose, maltose, sucrose, glucose, lactose, dextran, and aminoglycosides.

All publications, patents and patent documents are incorporated by reference herein, as though individually incorporated by reference. The
20 invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

The following Examples are intended to illustrate but not limit the
25 invention.

Materials: DSPE was purchased from Avanti Polar Lipids (Birmingham, AL) and methoxy-polyethyleneglycol-distearoylphosphatidylethanolamine (mPEG-DSPE, mPEG MW 2000 Daltons) was obtained from Sygena, Inc.

(Cambridge, MA). Cholesterol was obtained from Slovay Pharmaceuticals (Veenedaal, The Netherlands). HSPC was made by Lipoid K.G. (Ludwigshafen, Germany). Cisplatin was obtained from W.C. Heraeus GmbH (Hanau, Germany).

5

Methods:1. Liposome Particle Size

Liposome particle size was determined by dynamic light scattering using a Coulter model N4MD (Coulter Corp, Miami, FL). Unless noted otherwise, each
10 liposome composition was diluted about 300-fold with 0.9% (w/v) NaCl before measuring at DSL measurement with a light beam at varying angles (90° and 30°). Measurements were made in triplicate at 20°C.

2. Percent Encapsulation of Cisplatin

15 Liposomes were separated from free drug by gel exclusion chromatography, with fractions analyzed for total Pt content by flame atomic absorption spectroscopy using a Perkin-Elmer model 3110.

3. Turbidity

20 Liposomes were diluted 5-fold with 0.9% (w/v) NaCl before measuring optical density at 650nm ($OD_{650\text{ nm}}$) at room temperature, using 0.9% NaCl (w/v) as a blank. The relative change in turbidity caused by freezing and thawing is defined as the ratio of $OD_{650\text{ nm}}$ (frozen and thawed)-to- $OD_{650\text{ nm}}$ (never frozen).

Example 1

Cryoprotection in Presence of Osmotic Gradient

5 A. Placebo Liposome Preparation: Internal Sucrose

The lipids HSPC, cholesterol and mPEG-DSPE in a molar ratio of 51/44/5 were added to dehydrated ethanol at 60-65°C to give 0.002 moles of lipid per ml ethanol and mixed until dissolved, approximately 1 hour. The dissolved lipids were added to a solution of 0.9% (w/v) NaCl and 5% (w/v) sucrose in sterile water to yield a total lipid concentration of approximately 126 mg/ml. Samples were diluted after dialysis to a total lipid concentration of about 100 nM.

15 B. Placebo Liposome Preparation: No internal Sucrose

The lipids HSPC, cholesterol and mPEG-DSPE in a molar ratio of 51/44/5 were added to dehydrated ethanol at 60-65°C to give 0.002 moles of lipid per ml ethanol and mixed until dissolved, approximately 1 hour. The dissolved lipids were added to a solution of 0.9% (w/v) NaCl in sterile water to yield a total lipid concentration of approximately 126 mg/ml.

20 For both preparations described in A and B above, liposomes were hydrated at 60-65°C with mechanical stirring for approximately 1 hour before formation of unilamellar vesicles of approximately 120 nm diameter by extrusion at 60-65°C using polycarbonate membranes having 0.1 micron pore size. Ethanol was removed and the external aqueous medium was adjusted to 0.9% (w/v) NaCl and 5% (w/v) sucrose by dialysis.

25

C. Freezing and Thawing Conditions

A 3 mL, room temperature aliquot of the liposome suspensions formed in
5 A and B above were placed in a 10 mL clear glass serum vial. The vials were
placed in a conventional -20°C freezer 2.7 days. The samples were then
removed from the freezer and placed at room temperature to thaw.

10 D. Analysis of Samples

The particle size of the liposomes in each of the formulations after thawing
as well as control samples of each formulation (control meaning that the
sample was not frozen) were determined by dynamic light scattering. The
results are shown in Table 1.

15

Example 2

Liposome Formulations with Various NaCl External Concentrations

Liposomes were prepared by dissolving the lipids HSPC, cholesterol and
mPEG-DSPE in a molar ratio of 51/44/5 in dehydrated ethanol at 60-65°C to
20 give 0.002 moles of lipid per ml ethanol. The dissolved lipids were added to a
0.9% (w/v) NaCl to yield a total lipid concentration of approximately 126
mg/ml. The aqueous lipid solution was mixed to form liposomes. The
liposomes were subsequently down-sized by extrusion. After dialysis, the
total lipid was brought down to about 100 mM (prior to the 3-fold dilutions with
25 5% sucrose and 0.9%, 0.45%, or 0% NaCl, described below).

The external bulk medium was exchanged with a medium containing
0.9% (w/v) NaCl and 5% (w/v) sucrose by dialysis. The formulation was
diluted 3-fold with aqueous solutions of 5% (w/v) sucrose and 0.9%, 0.45% or
0% (w/v) NaCl, to yield an external medium of 5% (w/v) sucrose and 0.9%,

0.6% or 0.3% (w/v) NaCl.

Samples of each formulation were frozen for 4.9 days at -20°C. The samples were thawed by resting at room temperature and then the particle size was determined by dynamic light scattering. The results are shown in

5 Table 2.

Example 3

Liposome Preparations of Table 3

10 The liposome preparations set forth in Table 3 were prepared as described in Examples 1 and 2, with the following modifications:

(i) for half the samples the aqueous phase used for hydration was 0.9% NaCl and

for the other half it was 1.8% NaCl; and

15 (ii) the dilution after dialysis was done with histidine together with varying amounts of NaCl and sucrose to bring external [NaCl] and [sucrose] to the values shown in Table 3 and contained 0.5mM pyranine. Pyranine is a fluorescent probe that does not affect the results of the freeze/thaw experiment. All hydration media, in addition to NaCl contained 0.5mM
20 pyranine.

Example 4

Liposomes with Entrapped Cisplatin

Sterile water was heated to 63-67°C in a TEFLON-lined pressure
25 vessel and sodium chloride (0.9%) was added. Cisplatin was added at a concentration of 8.5 mg/ml and mixed until dissolved, approximately 15-25 minutes. 257.0 g PEG-DSPE, 719.4 g HSPC and 308.4 g cholesterol (molar ratio of 50.6/44.3/5.1) were added to 900 ml dehydrated ethanol at 60-65°C and mixed until dissolved, approximately 2 hours. The dissolved lipids were

added to 7670 g of drug solution to give a total lipid concentration of approximately 150 mg/ml.

The warm lipid solution was rapidly added to the warm (63-67°C) drug solution, with mixing, to form a suspension of liposomes having
5 heterogeneous sizes. The suspension was mixed for one hour at 63-67°C. The cisplatin concentration in the hydration mixture was 7.7 mg/ml and, at this stage, approximately 30% of the drug was encapsulated in the liposomes. 10% of the total solution volume was ethanol and the total lipid concentration was 150 mg lipid/ml.

10 The liposomes were sized to the desired mean particle diameter by controlled extrusion through polycarbonate filter cartridges housed in Teflon-lined stainless steel vessels. The liposome suspension was maintained at 63-65°C throughout the extrusion process, a period of 6-8 hours.

After sizing, the liposome suspension was cooled to 2-8°C overnight
15 and then warmed to room temperature (20-25°C) prior to filtering through a 1.2 µm 142-mm Gelman Versapor filter (acrylic copolymer on a Nylon 66 support) to remove precipitated drug.

A 0.9% (w/v) aqueous solution of NaCl was prepared by dissolving the NaCl in sterile water. The pH of the solution was adjusted to approximately
20 5.5 with 2 N HCl or NaOH. The solution was filtered through a 0.22 µm Durapore filter.

The liposome suspension was diluted in approximately a 1:1 (v/v) ratio with the NaCl solution and diafiltered through a polysulfone hollow-fiber ultrafilter. Eight volume exchanges were performed against the NaCl solution
25 to remove the ethanol and unencapsulated drug. The process fluid temperature was maintained at about 20-30°C. Total diafiltration time was approximately 4.5 hours.

The liposome suspension was then concentrated to approximately 1.2 mg cisplatin/ml by ultrafiltration. The post diafiltration process fluid was

analyzed for cisplatin content by HPLC. The liposomes had an internal phase of 7.7 mg/ml cisplatin in 0.9% NaCl and an external phase of aqueous 0.9% NaCl.

Samples of the liposome formulation were placed into glass vials, and
5 solid NaCl and sucrose were added to yield external NaCl concentrations of between 0.9-3.6% (w/v) and external sucrose concentrations of between about 1% to about 20% (w/v), assuming the volume of the external medium was 85% of the total volume before the addition of solids. Each sample was frozen at –
10 20°C for 6.8 days and then thawed by resting at room temperature. The mean particle size of the liposomes in each sample was determined as a measurement of extent of freezing damage. The results are shown in Table 4.

Although the invention has been described with respect to particular
15 embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the invention.

IT IS CLAIMED:

1. A liposome composition having protection from freeze/thaw damage comprising:

a suspension of liposomes wherein each liposome contains an
5 entrapped aqueous medium having an inner osmolarity, the liposomes being
suspended in an external medium composed of a water soluble salt and a
cryoprotectant, said external medium having an outer liposome osmolarity
higher than the inner liposome osmolarity thereby establishing a lower
inside/higher outside osmotic gradient across each liposome.

10

2. The composition of claim 1, wherein the external medium includes a
salt selected from the group consisting of nitrate salts, sodium salts,
potassium salts, ammonium salts, and sulfate salts.

15 3. The composition of claim 1, wherein the cryoprotectant is a
disaccharide sugar.

4. The composition of claim 1, wherein the cryoprotectant is a
monosaccharide sugar.

20

5. The composition of claim 1, wherein the cryoprotectant is selected
from the group consisting of trehalose, maltose, sucrose, glucose, lactose,
dextran, glycerol, polyethyleneglycol, and aminoglycosides.

25 6. The composition of claim 2, wherein the salt is selected from sodium
chloride (NaCl) and potassium chloride (KCl), or a combination thereof.

7. The composition of claim 1, further comprising a therapeutic agent
entrapped in the liposome.

8. The composition of claim 7, wherein the liposomes include a vesicle forming lipid derivatized with a hydrophilic polymer chain.

5

9. The composition of claim 8, wherein the therapeutic agent is cisplatin or a cisplatin analogue or derivative thereof.

10. A method for protecting a liposome composition from freeze/thaw
10 damage comprising:
preparing a suspension of liposomes wherein each liposome in the suspension comprises an entrapped aqueous medium having an inner osmolarity, the liposomes being suspended in an external medium comprised of a water soluble salt and a cryoprotectant, wherein the external medium
15 contains an outer liposome osmolarity higher than the inner liposome osmolarity thereby establishing a lower inside/higher outside osmotic gradient across each liposome.

11. The method of claim 10, wherein the external medium includes a
20 salt selected from the group consisting of nitrate salts, sodium salts, potassium salts, ammonium salts, and sulfate salts.

12. The method of claim 10, wherein the cryoprotectant is a disaccharide sugar.

25

13. The method of claim 10, wherein the cryoprotectant is a monosaccharide sugar.

14. The method of claim 10, wherein the cryoprotectant is selected from the group consisting of trehalose, maltose, sucrose, glucose, lactose, dextran, glycerol, polyethyleneglycol, and aminoglycosides.

5 15. The method of claim 11, wherein the salt is selected from sodium chloride (NaCl) and potassium chloride (KCl), or a combination thereof.

16. A method for protecting a liposome composition containing a metal coordination compound against freeze/thaw damage comprising:

10 preparing a suspension of liposomes, wherein each liposome in the suspension comprises an entrapped aqueous medium having an inner liposome osmolarity and the metal coordination compound, the liposomes being suspended in an external medium composed of a water soluble salt and a cryoprotectant, wherein the external medium contains an outer
15 liposome osmolarity higher than the inner liposome osmolarity thereby establishing a lower inside/higher outside osmotic gradient across each liposome.

17. The method of claim 16, wherein the metal coordination compound
20 is cisplatin or a cisplatin analogue or derivative thereof.

18. The method of claim 17, wherein the salt in the external medium is NaCl and the cryoprotectant is sucrose.

25 19. A method for improving freezing a suspension of liposomes comprising:

 combining in the suspension of liposomes a cryoprotectant and a water soluble salt effective to establish an osmotic gradient across each liposome, the suspension medium having a higher osmolarity than the liposome interior.

20. The method of claim 19, wherein the osmotic gradient is at least 100 mOsm.

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05372 A3

- (51) International Patent Classification⁷: **A61K 9/127**
- (21) International Application Number: **PCT/US00/19393**
- (22) International Filing Date: **14 July 2000 (14.07.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/144,380 **16 July 1999 (16.07.1999)** **US**
- (71) Applicant: **ALZA CORPORATION [US/US];** 1900
Charleston Road, P.O. Box 7210, Mountain View, California 94039-7210 (US).
- (72) Inventors: **ABRA, Robert, M.;** 143 Judson Avenue, San Francisco, CA 94112 (US). **DIBBLE, Andrew, R.;** Apt. #241, 2951 College Avenue, Livermore, CA 94550 (US).
- (74) Agents: **SIMBOLI, Paul, B. et al.;** ALZA Corporation, 1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *with international search report*
- (88) Date of publication of the international search report:
26 July 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **A LIPOSOME COMPOSITION HAVING RESISTANCE TO FREEZE/THAW DAMAGE**

(57) Abstract: A liposome composition having improved protection from freeze/thaw damage is described. The liposome composition contains an osmotic gradient across the liposome lipid bilayer, wherein the osmolarity of the external medium is higher than the osmolarity of the liposome inner medium. Typically, the external medium includes a salt and a cryoprotectant to achieve the increase observed in osmolarity.



WO 01/05372 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/19393

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 883 665 A (KOICHIRO MIYAZIMA, ET AL.) 28 November 1989 (1989-11-28) the whole document	1-20
A	--- KOICHIRO MIYAJIMA, ET AL.: "Effect of Saccharides on the Freezing and Thawing of Liposome Dispersion" CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 34, no. 7, July 1986 (1986-07), pages 2689-2697, XP002157891 the whole document -----	1-20

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

19 January 2001

Date of mailing of the international search report

06/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/19393

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4883665 A	28-11-1989	CA 1256372 A	27-06-1989
		JP 6104622 B	21-12-1994
		JP 62030708 A	09-02-1987
<hr/>			

THIS PAGE BLANK (USPTO)